factual

Biotech VC Targets 3-4x Returns, Not Power Law

Unlike tech venture capital, where a 1000-to-1 upside lets investors win only 1 in 100, biotech venture returns are not gigantic: a 10x return is wonderful and rare, and the target is 3 to 4x, with 5x a great outcome, so biotech investors cannot afford to be wrong as often.

factualpending

Speaker

Tal Zaks

Evidence Quote

“Our returns are not gigantic. To get a 10x return for us is wonderful, not something you see commonly. And to get a larger than 10x return is rare. So we shoot for 3 to 4x returns.”

Source

Bridging Science, Medicine, and Returns— Invest Like the Best
Created: 11/19/2026, 4:01:33 PM

Your notes

Loading notes...